Pack of 10 vials2 in stockSave 17%Tesamorelin 5 mg
Stabilized GHRH analog
Tesamorelin GHRH analogue research peptide, Australian-shipped. Lab-verified ≥99% purity.
Research Use Only. This compound is sold strictly for in-vitro research and laboratory purposes and is not intended for human consumption or therapeutic use. By purchasing you confirm you are a qualified researcher and agree to our full disclaimer.
Only 2 packs left
Stabilized growth hormone releasing hormone analog studied for effects on visceral adipose tissue and IGF-1 axis activity in research models.
Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH) — modified to extend its half-life relative to native GHRH. It is one of the most studied GHRH-analogue research peptides and the only one of its class to have undergone regulatory approval in any jurisdiction (for HIV-associated lipodystrophy, in the US, under the brand name Egrifta). Quantum Labs supplies Tesamorelin as a lyophilised powder for Australian research applications.
Research on Tesamorelin has covered models of growth-hormone secretion, body composition, lipid metabolism, and IGF-1 dynamics. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mechanism
Studied for selective binding to the GHRH receptor with extended half-life. Research associated with reduced visceral fat markers and elevated IGF-1 in study populations.
HPLC verified against a ≥99% purity specification. Independently tested by accredited third-party laboratories.
Tesamorelin — frequently asked questions
What is Tesamorelin?
Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). It is studied in growth-hormone research and pre-clinical models of metabolic regulation and body composition.
Is Tesamorelin legal in Australia?
Tesamorelin is not approved as a therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Tesamorelin for research use only.
What is the difference between Tesamorelin and CJC-1295?
Both are GHRH-analogue research peptides. CJC-1295 has a longer half-life and a stronger ability to extend the duration of GH pulses; Tesamorelin's modifications produce a shorter-acting but well-characterised GHRH-mimicking profile. They are studied as parallel research tools for different aspects of GHRH-pathway signalling.
What is the typical Tesamorelin research dosage?
Published clinical research (in the US, for the approved indication) has used 2 mg daily subcutaneous Tesamorelin. Research-protocol dosing varies by model. Human therapeutic dosing is not established in Australia.
Guides related to Tesamorelin
Researchers also explore
FeaturedPack of 10 vialsSave 25%Retatrutide
Lyophilized powder10 mg · 8 strengths
Tri-agonist GLP-1 / GIP / glucagon research peptide
In 1 stack
Pack of 10 vialsSave 22%MOTS-c
Lyophilized powder10 mg · 2 strengths
Mitochondrial-derived metabolic peptide
In 2 stacks
Pack of 10 vialsSave 18%5-Amino-1MQ
Lyophilized powder50 mg · 3 strengths
NNMT inhibitor research compound